> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-236/
- Published: 2019-09-02T12:00:00.000Z
- Updated: 2026-09-15T01:47:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144911

[**CDRH Seeks to Fill Vacancies on Device Panels**](https://www.fdaweb.com/cdrh-seeks-to-fill-vacancies-on-device-panels/)  
*Federal Register* notice: FDA requests nominations for voting members to serve on CDRH’s Device Good Manufacturing Practice Advisory Committee and the Medical Devices Advisory Committee panels. 08/30/2019

[**Docket No. on Pediatric Rare Disease Corrected**](https://www.fdaweb.com/docket-no-on-pediatric-rare-disease-corrected/)  
*Federal Register* notice: FDA corrects the docket number in a 12/2017 notice entitled “Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model.” 08/30/2019

[**9 Bulk Drugs Proposed for Compounding Exclusion**](https://www.fdaweb.com/9-bulk-drugs-proposed-for-compounding-exclusion/)  
*Federal Register* notice: FDA seeks comments on nine bulk drug substances that it is proposing not to allow outsourcing facilities to use in drug compounding. 08/30/2019

[**Regulatory Review Period for Puma’s Nerlynx**](https://www.fdaweb.com/regulatory-review-period-for-pumas-nerlynx/)  
*Federal Register* notice: FDA determines the regulatory review period for patent extension purposes for Puma Bio’s Nerlynx (neratinib). 08/30/2019

[**Submissions Extended for Quality Metrics Feedback**](https://www.fdaweb.com/submissions-extended-for-quality-metrics-feedback/)  
*Federal Register* notice: FDA extends the submission period related to a 6/29 notice on its drug Quality metrics feedback program. 08/29/2019

[**Guide on Cancer Trial Placebo Use & Blinding**](https://www.fdaweb.com/guide-on-cancer-trial-placebo-use-blinding/)  
*Federal Register* notice: FDA releases a final guidance on using placebos and allowing blinding in cancer clinical trials. 08/29/2019

[**Comments Reopened on Dronabinol Scheduling**](https://www.fdaweb.com/comments-reopened-on-dronabinol-scheduling/)  
*Federal Register* notice: FDA reopens the comment period for a 3/1 notice on international drug scheduling for Dronabinol.08/28/2019

[**Guide on Drugs for Treating Male Breast Cancer**](https://www.fdaweb.com/guide-on-drugs-for-treating-male-breast-cancer/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Male Breast Cancer: Developing Drugs for Treatment.” 08/27/2019